FIGO + IMS: HT for POI and Early Menopause, a Healthy-Aging Paradigm (Aug 2026)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: FIGO / International Menopause Society (via Climacteric + IJGO) · Published: August 18, 2026 · Accessed: August 24, 2026

Visit the source ↗

Claims this source supports

• Premature ovarian insufficiency (POI) and early menopause affect millions of women worldwide; compared with normal menopause they mean a longer duration of estrogen deficiency, associated not only with a shorter lifespan but with a reduced healthspan, owing to increased cardiovascular, skeletal, cognitive and psychological morbidity, and sexual health impacts.
• The joint FIGO and IMS position paper (Benedetto C, Khadilkar SS, Nappi RE, Genazzani AR, Frezet F, Cucinella L, Divakar H, Anagnostis P, Panay N) calls for recognizing POI and early menopause as chronic endocrine disorders rather than mere variations of normal menopause, proposing that timely and adequate hormone therapy, along with preventive strategies, should be foundational in managing these conditions.
• The paper calls for a coordinated global effort to improve awareness, education, and access to care for women affected by POI and early menopause.
• Published August 2026 in Climacteric, the journal of the International Menopause Society (DOI 10.1080/13697137.2026.2691828), and in the International Journal of Gynecology & Obstetrics (DOI 10.1002/ijgo.71217; PubMed 42609071), with a FIGO news announcement titled 'Call for new approach to hormone therapy in POI and early menopause'.